Your browser doesn't support javascript.
loading
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.
Hsu, Jessie Hao-Ru; Hubbell-Engler, Benjamin; Adelmant, Guillaume; Huang, Jialiang; Joyce, Cailin E; Vazquez, Francisca; Weir, Barbara A; Montgomery, Philip; Tsherniak, Aviad; Giacomelli, Andrew O; Perry, Jennifer A; Trowbridge, Jennifer; Fujiwara, Yuko; Cowley, Glenn S; Xie, Huafeng; Kim, Woojin; Novina, Carl D; Hahn, William C; Marto, Jarrod A; Orkin, Stuart H.
Afiliación
  • Hsu JH; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Hubbell-Engler B; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Adelmant G; Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Huang J; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Joyce CE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts.
  • Vazquez F; Department of Cancer Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Weir BA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Montgomery P; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Tsherniak A; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Giacomelli AO; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Perry JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Trowbridge J; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Fujiwara Y; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine.
  • Cowley GS; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Xie H; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Kim W; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Novina CD; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Hahn WC; Department of Cancer Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Marto JA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Orkin SH; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Cancer Res ; 77(17): 4613-4625, 2017 09 01.
Article en En | MEDLINE | ID: mdl-28655788
ABSTRACT
Through an shRNA screen, we identified the protein arginine methyltransferase Prmt1 as a vulnerable intervention point in murine p53/Rb-null osteosarcomas, the human counterpart of which lacks effective therapeutic options. Depletion of Prmt1 in p53-deficient cells impaired tumor initiation and maintenance in vitro and in vivo Mechanistic studies reveal that translation-associated pathways were enriched for Prmt1 downstream targets, implicating Prmt1 in translation control. In particular, loss of Prmt1 led to a decrease in arginine methylation of the translation initiation complex, thereby disrupting its assembly and inhibiting translation. p53/Rb-null cells were sensitive to p53-induced translation stress, and analysis of human cancer cell line data from Project Achilles further revealed that Prmt1 and translation-associated pathways converged on the same functional networks. We propose that targeted therapy against Prmt1 and its associated translation-related pathways offer a mechanistic rationale for treatment of osteosarcomas and other cancers that exhibit dependencies on translation stress response. Cancer Res; 77(17); 4613-25. ©2017 AACR.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Biosíntesis de Proteínas / Neoplasias Óseas / Osteosarcoma / Proteína p53 Supresora de Tumor / Proteína de Retinoblastoma Límite: Animals Idioma: En Revista: Cancer Res Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Biosíntesis de Proteínas / Neoplasias Óseas / Osteosarcoma / Proteína p53 Supresora de Tumor / Proteína de Retinoblastoma Límite: Animals Idioma: En Revista: Cancer Res Año: 2017 Tipo del documento: Article